A Case of a 54-Year-Old Woman with VMS and Cardiovascular Considerations

In "A Case of a 54-Year-Old Woman with VMS and Cardiovascular Considerations," our panel explores the critical role of primary care in the identification and management of vasomotor symptoms, using a new patient case to ground their discussion. The experts affirm that this type of patient is highly representative of those seen in everyday primary care practice, and emphasize that primary care providers are often the first — and sometimes only — point of contact for women navigating the menopause transition, particularly those who have stopped seeing a gynecologist after completing childbearing.

The conversation highlights how misinformation stemming from the Women's Health Initiative (WHI) has created a generation of both patients and providers who are unnecessarily fearful of or uninformed about menopause treatment options. The experts note that when trusted clinicians dismiss or minimize VMS — even unintentionally — patients are unlikely to seek a second opinion, making it all the more important that primary care providers feel confident and equipped to address these concerns. They stress that managing VMS is well within the scope of primary care and encourage providers to build this into their clinical tool belt.

The panel also observes a significant shift in patient awareness over the past three to five years, driven in part by social media, with more women arriving at appointments informed and advocating for themselves. While this empowerment is largely welcomed, the experts note that it also requires clinicians to slow the conversation down to ensure patients receive a full, nuanced picture of their treatment options, including a thorough discussion of individual risks and benefits.

Our next episode, "Transdermal Hormone Therapy for VMS and Cardiovascular Risk Management," features the experts examining the cardiovascular risk profile of a 54-year-old African American woman with VMS, and discussing the rationale for selecting transdermal estradiol with micronized progesterone as a first-line hormonal treatment option.